ClinicalTrials.gg
CompletedNCT01282463Updated Sep 9, 2019Results posted

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

A Phase 2 interventional study of Docetaxel and Ramucirumab DP in Carcinoma of Urinary Tract, Urethral Carcinoma and Carcinoma of Ureter, sponsored by Eli Lilly and Company. Completed at 32 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-09.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Urethral Neoplasms with a site in United States — 4 open to participants now, 17 under way, 1 of them phase 3. Urethral Neoplasms · United States.

Enrollment
14th of 69
148 · median 44
Started
2011
with 3 others
Phase 2
39 of 76
1 open now
Registered
40th of 76
by date
Lead sponsor
3 of 76
Eli Lilly and Company

Among the 76 studies in Urethral Neoplasms with a site in United States, this one is the 14th largest by enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2011, is one of 39 in phase 2, and was the 40th registered.

Urethral Neoplasms

95 studies on the registry are indexed under Urethral Neoplasms; 5 are open to participants now.

Browse Urethral Neoplasms studies →

Open to participants now

4 of the 76 studies in Urethral Neoplasms with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Urethral Neoplasms studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Urethral Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens. Participants will be enrolled into 1 of 3 treatment arms: docetaxel; docetaxel and ramucirumab; or docetaxel and icrucumab.

03

Conditions studied

  • Carcinoma of Urinary Tract
  • Urethral Carcinoma
  • Carcinoma of Ureter
  • Carcinoma of Renal Pelvis

Keywords

  • Carcinoma, Renal Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis
  • Locally advanced or and unresectable transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis
  • Had treatment with a platinum-containing regimen
  • Disease progression within 12 months of after receiving the last dose of a platinum containing regimen in the or adjuvant setting, and/or had disease progression while on a platinum-containing regimen or within 12 months after the last dose of therapy in the locally advanced or metastatic setting
  • Has measurable or nonmeasurable disease
  • of ≥ 3 months
  • Received no more than 2 prior systemic chemotherapy regimens in any setting
  • Has an (ECOG) performance status of 0-1
  • Has adequate hematologic, coagulation, hepatic and renal function
  • Does not have:

    • cirrhosis at a level of B (or worse)
    • cirrhosis (any degree) and a history of hepatic encephalopathy or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis
  • If female, is surgically sterile, , or compliant with a highly effective method during and for 12 weeks after the treatment period
  • If male, the patient is surgically sterile or compliant with a contraceptive regimen during and for 12 weeks after the treatment period

Exclusion criteria

Exclusion Criteria:

  • Received more than one prior systemic treatment regimen for disease
  • Received prior systemic taxane therapy (except for prior paclitaxel therapy) for Transitional Cell Carcinoma of the bladder, urethra, ureter, or renal pelvis in any setting (, adjuvant, metastatic). Prior intravesical taxane therapy is allowed
  • Has received more than one prior anti-angiogenic agent for Transitional Cell Carcinoma of the bladder, urethra, ureter, or renal pelvis
  • Has received radiation therapy within 4 weeks prior to randomization
  • Has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders
  • Has experienced a Grade ≥ 3 bleeding event (eg, via gastric ulcers, gastric varices, or gross hematuria) within 3 months prior to randomization
  • Has uncontrolled intercurrent illness including, but not limited to symptomatic anemia, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders
  • Has experienced any arterial thrombotic or thromboembolic events, including but not limited to myocardial infarction, or cerebrovascular accident, within 6 months prior to randomization
  • Has known , uncontrolled spinal cord compression, or
  • Has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy
  • Has known infection or acquired immunodeficiency syndrome
  • Has received a prior autologous or allogeneic organ or tissue transplantation
  • Received chemotherapy within 21 days prior to randomization; and/or is currently enrolled in, or discontinued within 21 days prior to randomization from, a clinical trial involving an product or unapproved use of a drug or device (other than the study drug[s] used in this study), or is concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study; and/or was treated with anti-angiogenic therapy within 28 days prior to randomization
  • Has undergone major surgery within 28 days prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization
  • Has had a serious nonhealing wound, ulcer, or bone fracture within 28 days prior to randomization
  • Has an elective or planned major surgery to be performed during the course of the trial
  • Is pregnant or lactating
  • Has a concurrent active other than adequately treated non-melanomatous skin cancer, curatively treated cervical carcinoma in-situ, other noninvasive carcinoma or in-situ neoplasm, or prostate cancer with an undetectable prostate specific antigen (PSA) and no current treatment with hormone therapy
  • Has an acute/subacute bowel obstruction or history of chronic diarrhea requiring ongoing medical intervention
  • History of gastrointestinal perforation and/or fistula within 6 months prior to randomization
  • Has active diverticulitis
  • Known to docetaxel or other drugs formulated with polysorbate 80
  • Known hypersensitivity to agents of similar biologic composition as ramucirumab DP, IMC-18F1, or other agents that specifically target vascular endothelial growth factor receptor (VEGF)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (actual)

Study arms

  • Active comparator
    Docetaxel

    Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.

    Drug: Docetaxel

  • Experimental
    Docetaxel + Ramucirumab DP

    Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.

    Drug: Docetaxel · Biological: Ramucirumab DP

  • Experimental
    Docetaxel + Icrucumab

    Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.

    Drug: Docetaxel · Biological: Icrucumab

Interventions

  • Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle

  • BiologicalRamucirumab DP

    Ramucirumab (DP): 10 milligram/kilogram (mg/kg) intravenous (IV) on day 1 of each 21-day cycle

    Also known as: IMC-1121B, LY3009806

  • BiologicalIcrucumab

    12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle

    Also known as: IMC-18F1, LY3012212

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS time was the time from randomization until the date of objectively determined progressive disease (PD) or death due to any cause, whichever occurred first. According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD who were alive at the end of the follow-up period (or lost to follow-up) were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.

    Time frame: Randomization to Measured PD or Death From Any Cause (Up To 40 Months)

Secondary outcomes

  1. Percentage of Participants Achieving Objective Response Rate (ORR)

    Participants achieved an objective response if they had a best overall response of partial response (PR) or complete response (CR). According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels \[if tumor markers were initially above the upper limit of normal (ULN)\]. The percentage of participants who achieved an objective response=(number of participants with CR or PR)/(number of participants assessed)\*100.

    Time frame: Randomization to Measured PD (Up to 40 Months)

  2. Duration of Response

    The duration of response was measured from the time measurement criteria were first met for a CR or PR (whichever was first recorded) until the first date of objectively documented progressive disease (taking as a reference for progressive disease the smallest measurement recorded since randomization) or the date of death, whichever occurred first. Data for participants who did not relapse or die were censored at the day of their last adequate tumor assessment. Duration of response was estimated by the Kaplan-Meier method.

    Time frame: First Criteria Met for CR or PR to Measured PD or Death From Any Cause (Up to 40 Months)

  3. Number of Participants With Adverse Events (AEs)

    A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Up To 41.7 Months

  4. Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab

    Time frame: Cycle 1:Predose,1 hour(hr) post End of Infusion (EOI),48hr,72hr,168hr,336hr post-EOI;Cycle2:Predose,1hr post-EOI; Cycle3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI; Cycle4:Predose,1hr post-EOI;Cycle6 and every other cycle thereafter:Predose,1hr Post EOI

  5. PK: Minimum Concentration (Cmin) Ramucirumab

    Time frame: Cycle 2:Predose,1hr post-EOI;Cycle3:Predose,1hr,48hr,72hr,168hr,336hr, post-EOI;Cycle4:Predose,1hr post-EOI;Cycle6:Predose,1hr Post EOI

  6. PK: Cmax Icrucumab

    Time frame: Cycle 1:Predose,1 hr post-EOI, 48hr, 72hr Post-EOI; Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI

  7. PK: Cmin Icrucumab

    Time frame: Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI

  8. Number of Participants With Serum Anti-Ramucirumab Antibody Assessment

    Number of participants with at least one positive titer treatment emergent antibody positive neutralizing antibody detecting. A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals.

    Time frame: Cycle 1:Predose,EOI,1hr,48hr,72hr,168hr,336 hr post-EOI:Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI;Cycle 4:Predose,1hr post-EOI;Cycle 6:Predose,1hr post-EOI

  9. Number of Participants With Serum Anti-Icrucumab Antibody Assessment

    A sample will be considered positive for anti-Icrucumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-IMC-Icrucumab antibody level seen in healthy untreated individuals.

    Time frame: Cycle 1 Day 1 and Day 8 Predose and 1hr Post Dose

  10. Pharmacodynamics (PD): Change in Circulating Levels of Placental Growth Factor (PlGF)

    Time frame: 40 months

  11. PD: Change in Circulating Levels of Vascular Endothelial Growth Factor-A (VEGF-A)

    Time frame: 40 months

  12. PD: Change in Circulating Levels of Vascular Endothelial Growth Factor-B (VEGF-B)

    Time frame: 40 months

  13. PD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-1 (VEGFR-1)

    Time frame: 40 months

  14. PD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-2 (VEGFR-2)

    Time frame: 40 months

07

Results

Posted Jul 2, 2019

Participant flow

Participant flow — Overall Study
MilestoneDocetaxelDocetaxel + Ramucirumab DPDocetaxel + Icrucumab
Started494950
Received at least 1 dose of study drug454649
Completed414546
Not completed844
Withdrew: Lost to follow-up100
Withdrew: Withdrawal by subject623
Withdrew: Never treated "death"010
Withdrew: Never treated "pd"010
Withdrew: Protocol violation001
Withdrew: Physician decision100

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS time was the time from randomization until the date of objectively determined progressive disease (PD) or death due to any cause, whichever occurred first. According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD who were alive at the end of the follow-up period (or lost to follow-up) were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.

Time frame:
Randomization to Measured PD or Death From Any Cause (Up To 40 Months)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsDocetaxelDocetaxel + Ramucirumab DPDocetaxel + Icrucumab
Progression-Free Survival (PFS)2.8 (1.9 to 3.6)5.4 (3.1 to 6.9)1.6 (1.4 to 5.4)
SecondaryPercentage of Participants Achieving Objective Response Rate (ORR)

Participants achieved an objective response if they had a best overall response of partial response (PR) or complete response (CR). According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels \[if tumor markers were initially above the upper limit of normal (ULN)\]. The percentage of participants who achieved an objective response=(number of participants with CR or PR)/(number of participants assessed)\*100.

Time frame:
Randomization to Measured PD (Up to 40 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Objective Response Rate (ORR)
percentage of participantsDocetaxelDocetaxel + Ramucirumab DPDocetaxel + Icrucumab
Percentage of Participants Achieving Objective Response Rate (ORR)8.9 (2.5 to 21.2)23.9 (12.6 to 38.8)12.2 (4.6 to 24.8)
SecondaryDuration of Response

The duration of response was measured from the time measurement criteria were first met for a CR or PR (whichever was first recorded) until the first date of objectively documented progressive disease (taking as a reference for progressive disease the smallest measurement recorded since randomization) or the date of death, whichever occurred first. Data for participants who did not relapse or die were censored at the day of their last adequate tumor assessment. Duration of response was estimated by the Kaplan-Meier method.

Time frame:
First Criteria Met for CR or PR to Measured PD or Death From Any Cause (Up to 40 Months)
Reported as:
Median · months
Duration of Response
monthsDocetaxelDocetaxel + Ramucirumab DPDocetaxel + Icrucumab
Duration of Response4.6 (2.6 to 5.6)4.6 (0.7 to 7.0)NA (2.9 to NA)
SecondaryNumber of Participants With Adverse Events (AEs)

A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Up To 41.7 Months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsDocetaxelDocetaxel + Ramucirumab DPDocetaxel + Icrucumab
Any AE454649
Any SAE192522
SecondaryPharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab
Time frame:
Cycle 1:Predose,1 hour(hr) post End of Infusion (EOI),48hr,72hr,168hr,336hr post-EOI;Cycle2:Predose,1hr post-EOI; Cycle3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI; Cycle4:Predose,1hr post-EOI;Cycle6 and every other cycle thereafter:Predose,1hr Post EOI
Reported as:
Geometric mean · microgram/milliliter (ug/mL)
Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab
microgram/milliliter (ug/mL)Docetaxel + Ramucirumab DP
Cycle 1258 ± 27
Cycle 2304 ± 31
Cycle 3300 ± 13
Cycle 4279 ± 40
Cycle 6252 ± 57
SecondaryPK: Minimum Concentration (Cmin) Ramucirumab
Time frame:
Cycle 2:Predose,1hr post-EOI;Cycle3:Predose,1hr,48hr,72hr,168hr,336hr, post-EOI;Cycle4:Predose,1hr post-EOI;Cycle6:Predose,1hr Post EOI
Reported as:
Geometric mean · microgram/milliliter (ug/mL)
PK: Minimum Concentration (Cmin) Ramucirumab
microgram/milliliter (ug/mL)Docetaxel + Ramucirumab DP
Cycle 219.5 ± 56
Cycle 339.9 ± 34
Cycle 435.3 ± 60
Cycle 631.2 ± 61
SecondaryPK: Cmax Icrucumab
Time frame:
Cycle 1:Predose,1 hr post-EOI, 48hr, 72hr Post-EOI; Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI
Reported as:
Geometric mean · ug/mL
PK: Cmax Icrucumab
ug/mLDocetaxel + Icrucumab
Cycle 1 Cmax474 ± 45
Cycle 3 Cmax599 ± 27
SecondaryPK: Cmin Icrucumab
Time frame:
Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI
Reported as:
Geometric mean · ug/mL
PK: Cmin Icrucumab
ug/mLDocetaxel + Icrucumab
Day 1 Cycle 2NA ± NA
Day 1 Cycle 3153 ± 66
SecondaryNumber of Participants With Serum Anti-Ramucirumab Antibody Assessment

Number of participants with at least one positive titer treatment emergent antibody positive neutralizing antibody detecting. A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals.

Time frame:
Cycle 1:Predose,EOI,1hr,48hr,72hr,168hr,336 hr post-EOI:Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI;Cycle 4:Predose,1hr post-EOI;Cycle 6:Predose,1hr post-EOI
Reported as:
Count of participants · Participants
Number of Participants With Serum Anti-Ramucirumab Antibody Assessment
ParticipantsDocetaxel + Ramucirumab DP
Number of Participants With Serum Anti-Ramucirumab Antibody Assessment1
SecondaryNumber of Participants With Serum Anti-Icrucumab Antibody Assessment

A sample will be considered positive for anti-Icrucumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-IMC-Icrucumab antibody level seen in healthy untreated individuals.

Time frame:
Cycle 1 Day 1 and Day 8 Predose and 1hr Post Dose

No measurements were reported for this outcome.

SecondaryPharmacodynamics (PD): Change in Circulating Levels of Placental Growth Factor (PlGF)
Time frame:
40 months

No measurements were reported for this outcome.

SecondaryPD: Change in Circulating Levels of Vascular Endothelial Growth Factor-A (VEGF-A)
Time frame:
40 months

No measurements were reported for this outcome.

SecondaryPD: Change in Circulating Levels of Vascular Endothelial Growth Factor-B (VEGF-B)
Time frame:
40 months

No measurements were reported for this outcome.

SecondaryPD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-1 (VEGFR-1)
Time frame:
40 months

No measurements were reported for this outcome.

SecondaryPD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-2 (VEGFR-2)
Time frame:
40 months

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel—19/45 (42.2%)45/45 (100%)
Docetaxel + Ramucirumab DP—25/46 (54.3%)46/46 (100%)
Docetaxel + Icrucumab—22/49 (44.9%)49/49 (100%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventDocetaxelDocetaxel + Ramucirumab DPDocetaxel + Icrucumab
Febrile neutropeniaBlood and lymphatic system disorders5/459/463/49
NeutropeniaBlood and lymphatic system disorders2/454/462/49
PneumoniaInfections and infestations1/454/461/49
SepsisInfections and infestations2/454/460/49
Small intestinal obstructionGastrointestinal disorders1/453/461/49
PyrexiaGeneral disorders0/453/460/49
Urinary tract infectionInfections and infestations1/453/463/49
AnaemiaBlood and lymphatic system disorders2/451/462/49
DehydrationMetabolism and nutrition disorders2/451/462/49
HaematuriaRenal and urinary disorders2/452/461/49
Most frequent other events
Showing 10 of 101
Most frequent other events
EventDocetaxelDocetaxel + Ramucirumab DPDocetaxel + Icrucumab
FatigueGeneral disorders36/4538/4638/49
AlopeciaSkin and subcutaneous tissue disorders22/4527/4626/49
Decreased appetiteMetabolism and nutrition disorders19/4526/4625/49
DiarrhoeaGastrointestinal disorders11/4525/4622/49
NauseaGastrointestinal disorders12/4524/4624/49
Oedema peripheralGeneral disorders9/4517/4624/49
EpistaxisRespiratory, thoracic and mediastinal disorders4/4520/460/49
AnaemiaBlood and lymphatic system disorders10/4511/4620/49
CoughRespiratory, thoracic and mediastinal disorders4/4518/4616/49
DysgeusiaNervous system disorders17/4514/4616/49

Baseline characteristics

All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)DocetaxelDocetaxel + Ramucirumab DPDocetaxel + IcrucumabTotal
Mean66.6 ± 11.4566.7 ± 9.0664.1 ± 10.3865.7 ± 10.33
Sex: Female, Male
Sex: Female, Male(Participants)DocetaxelDocetaxel + Ramucirumab DPDocetaxel + IcrucumabTotal
Female1091130
Male353738110
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DocetaxelDocetaxel + Ramucirumab DPDocetaxel + IcrucumabTotal
Hispanic or Latino4329
Not Hispanic or Latino414347131
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DocetaxelDocetaxel + Ramucirumab DPDocetaxel + IcrucumabTotal
American Indian or Alaska Native0000
Asian52411
Native Hawaiian or Other Pacific Islander0000
Black or African American2024
White364342121
More than one race2114
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)DocetaxelDocetaxel + Ramucirumab DPDocetaxel + IcrucumabTotal
Canada30283795
United States15181245
08

Study locations

32 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Los Angeles, California 90033, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sacramento, California 95817, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Francisco, California 94115, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aurora, Colorado 80012, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Haven, Connecticut 06520, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Washington, District of Columbia 20037, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boca Raton, Florida 33486, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32224, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32806, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baltimore, Maryland 21231, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rochester, Minnesota 55902, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Las Vegas, Nevada 89169, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albany, New York 12208, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New York, New York 10032, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Oregon 97477, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charleston, South Carolina 29425, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashville, Tennessee 37203, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bedford, Texas 76022, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75246, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    McAllen, Texas 78503, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    The Woodlands, Texas 77380, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Webster, Texas 77598, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fairfax, Virginia 22031, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hampton, Virginia 23666, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seattle, Washington 98109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wenatchee, Washington 98801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edmonton, Alberta T6G 1Z2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kelowna, British Columbia V1Y5L3, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vancouver, British Columbia V5Z 4E6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, Ontario N6A 4L6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ottawa, Ontario K1H 8L6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toronto, Ontario M4X 1K9, Canada
09

References and documents

Publications

  • Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol. 2016 May 1;34(13):1500-9. doi: 10.1200/JCO.2015.65.0218. Epub 2016 Feb 29. PubMed 26926681 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Feb 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2019, 4 years 5 months after primary completion. A results delay was requested in May 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2011
First posted
Jan 25, 2011
Start
Apr 2011
Primary completionActual
Feb 2015
CompletionActual
Mar 2015
Results delay requested
May 8, 2015
Results first posted
Jul 2, 2019
Last update
Sep 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01282463
Responsible party
Sponsor
First posted
Jan 25, 2011
Start date
Apr 2011
Primary completion
Feb 2015
Completion
Mar 2015
Results posted
Jul 2, 2019
Last update
Sep 9, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ramucirumab · Icrucumab

Start the discussion